PTPI (Petros Pharmaceuticals) FCF Yield %: -2,306.69 (As of Jun. 26, 2026)


What is Petros Pharmaceuticals FCF Yield %?

Petros Pharmaceuticals PTPI FCF Yield % is -2,306.69 as of Jun. 26, 2026. Among 1,005 Drug Manufacturers companies, Petros Pharmaceuticals ranks worse than 99.8% on this metric.

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Petros Pharmaceuticals's Trailing 12-Month Free Cash Flow is $-5.86 Mil, and Market Cap is $0.25 Mil. Therefore, Petros Pharmaceuticals's FCF Yield % for today is -2,306.69%.

The historical rank and industry rank for Petros Pharmaceuticals's FCF Yield % or its related term are showing as below:

PTPI' s FCF Yield % Range Over the Past 10 Years
Min: -285183.01   Med: -202.44   Max: -23.89
Current: -2306.69


During the past 7 years, the highest FCF Yield % of Petros Pharmaceuticals was -23.89%. The lowest was -285183.01%. And the median was -202.44%.

PTPI's FCF Yield % is ranked worse than
99.8% of 1005 companies
in the Drug Manufacturers industry
Industry Median: 0.67 vs PTPI: -2306.69

Petros Pharmaceuticals's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.


Petros Pharmaceuticals FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


Petros Pharmaceuticals FCF Yield % Related Terms


Petros Pharmaceuticals FCF Yield % Historical Data

* Premium members only.

The historical data trend for Petros Pharmaceuticals's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Petros Pharmaceuticals FCF Yield % Chart

Petros Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Yield %
Get a 7-Day Free Trial -17.17 -264.69 -180.31 -63.39 -2,003.48

Petros Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -187.22 -849.11 -446.97 -1,111.36 -1,345.63

PTPI vs GCAN, KOAN, PNXP: FCF Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Petros Pharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Petros Pharmaceuticals FCF Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Petros Pharmaceuticals's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Petros Pharmaceuticals's FCF Yield % falls into.



Petros Pharmaceuticals FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Petros Pharmaceuticals's FCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

FCF Yield %=Free Cash Flow / Market Cap
=-6.735 / 0.33616575
=-2,003.48%

Petros Pharmaceuticals's annualized FCF Yield % for the quarter that ended in Mar. 2026 is calculated as

FCF Yield %=Free Cash Flow * Annualized Factor / Market Cap
=-0.784 * 4 / 0.2330515
=-1,345.63%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Yield % →
What does a FCF Yield % of -2,306.69 mean?
Petros Pharmaceuticals (PTPI) has a FCF Yield % of -2,306.69 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Petros Pharmaceuticals and its competitors. According to the industry distribution chart, Petros Pharmaceuticals ranks #1003 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 99.8%.
Is Petros Pharmaceuticals' FCF Yield % too high?
Petros Pharmaceuticals' current FCF Yield % is -2,306.69. Based on the distribution chart, Petros Pharmaceuticals ranks #1003 out of 1005 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Petros Pharmaceuticals' FCF Yield % compare to GCAN and KOAN?
According to the Drug Manufacturers industry distribution chart, Petros Pharmaceuticals ranks #1003 out of 1005 companies for FCF Yield %. This places Petros Pharmaceuticals in the lower half of its industry. The industry median FCF Yield % is 0.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Drug Manufacturers company?
The median FCF Yield % among Drug Manufacturers companies is 0.67, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Petros Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median FCF Yield % is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Petros Pharmaceuticals's current FCF Yield % is -2,306.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Petros Pharmaceuticals stock overvalued right now?
Petros Pharmaceuticals (PTPI) has a current FCF Yield % of -2,306.69. The current FCF Yield % is -2,306.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Petros Pharmaceuticals (PTPI), the current FCF Yield % is -2,306.69 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Petros Pharmaceuticals Business Description

Address 1185 Avenue of the Americas, 3rd Floor, New York, NY, USA, 10036
Petros Pharmaceuticals Inc is a men's health pharmaceutical company. The Company is working towards the goal of becoming an innovator in the emerging self-care market, driving expanded access to key nonprescription pharmaceuticals as Over-the-Counter and nonprescription drug products with additional conditions for nonprescription use (ACNU Products) treatment options. Petros is pursuing the development of a proprietary integrated technology solutions platform containing two components: SaaS, designed to assist pharmaceutical companies in operationalizing and commercializing an Rx-to-OTC switch as an element in the development of an ACNU Product, and a potential Software as a Medical Device component, which guides the consumer in navigating appropriate self-selection or deselection.